FIGURE 1.

Outcomes according to number of risk marker improvements (adjusted by baseline variables) among persons with type 2 diabetes. From Zobel EH et al. The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER and SUSTAIN 6 trials.¹² Abstract/FC 058 ©ERA‐EDTA GROUP. Reproduced by permission of Oxford University Press on behalf of the ERA‐EDTA. Figure is not published under this article's licence and permission must be sought for any form of reuse. HRs show risk for outcomes according to number of risk markers with a clinically relevant improvement among participants with type 2 diabetes. Post‐hoc analysis of data from the LEADER and SUSTAIN 6 trials included 11 678 persons with type 2 diabetes. Participants were categorized according to number of risk markers with an improvement at year 1 [none (group G0), one (G1), two (G2), three (G3) and four or more (G4)]. ^‡Compared G1‐G4 with G0 (the reference group); ^§test for trend was evaluated in a Cox regression model with number of risk marker improvements as a continuous variable adjusted for treatment and baseline levels of the risk markers. CI, confidence interval; CV, cardiovascular; HR, hazard ratio; IR, incidence rate per 100 patient years of observation; MACE, major adverse cardiovascular events